.jpg)
Biocan novel puppy, lyophilisate and solvent for suspension for injection for dogs
Combined vaccine against puppy distemper and parvovirosis, verified through challenges against three parvovirus strains CPV 2a, 2b, 2c, and against the CDV distemper virus.
Composition
One vaccination dose (1 ml) contains:
Active substances:
Lyophilisate Minimum Maximum
Canine Distemper virus, strain CDV Bio 11/A, live att. 104,1 TCID50 105,5 TCID50
Canine Parvovirus type 2b, strain CPV-2b Bio 12/B, live att. 105,5 TCID50 107,0 TCID50
* Tissue culture infectious dose – 50%
Lyophilised vaccine is spongy matter, white colour. Solvent is clear colourless liquid.
Target species
Dogs.
Indications for use, specifying the target species
Active immunization of dogs from 6 weeks of age:
- to prevent mortality and clinical signs caused by canine distemper virus
- to prevent clinical signs, leukopenia and viral excretion caused by canine parvovirus type 2a, 2b and 2c
Onset of immunity:
Immunity against CDV and CPV is developed within 14 days after a single dose in puppies free of maternally derived antibodies.
Duration of immunity:
The duration of immunity against CDV and CPV in puppies without maternally derived antibodies was after a single dose of Biocan Novel Puppy vaccine determined for 12 months. The duration of immunity against CDV and CPV type 2b was demonstrated serologically and by challenge, duration of immunity against CPV types 2a and 2c was demonstrated serologically.
Special warnings for each target species
Immunological responses to the CDV and CPV components may be delayed due to maternally derived antibody interference. In situations where very high maternally derived antibodies levels against CDV and CPV are expected, the vaccination with further doses of polyvalent Biocan Novel vaccines that also contain CDV and CPV should follow.
Special precautions for use
Special precautions for use in animals
Only clinically healthy animals should be vaccinated. The live virus vaccine strain CPV-2b can be spread to non-vaccinated animals but does not cause disease. Since the vaccine virus strain CPV-2b has not been tested in domestic cats and other carnivores (except dogs) that are known to be susceptible to canine parvoviruses, it is recommended vaccinated dogs to be separated from other canine and feline species after vaccination.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Therefore the use is not recommended during pregnancy and lactation.
Bioveta